Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-17
DOI
10.3389/fonc.2022.911876
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
- (2021) Manali Tilak et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- M2 macrophage-derived exosomal microRNAs inhibit cell migration and invasion in gliomas through PI3K/AKT/mTOR signaling pathway
- (2021) Jie Yao et al. Journal of Translational Medicine
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
- (2021) Javier Munoz et al. Targeted Oncology
- Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2021) Nian N. N. Maarof et al. Cancers
- Current treatment options for HER2-positive breast cancer patients with brain metastases
- (2021) Daniele Galanti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- RAS-targeted therapies
- (2021) Amanda R. Moore et al. NATURE REVIEWS DRUG DISCOVERY
- Sex-Specific Differences in Glioblastoma
- (2021) Anna Carrano et al. Cells
- Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
- (2020) Fumi Higuchi et al. CLINICAL CANCER RESEARCH
- KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway
- (2020) Yang Gao et al. JOURNAL OF NEURO-ONCOLOGY
- c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein
- (2020) Severa Bunda et al. MOLECULAR CANCER RESEARCH
- Tackling the Many Facets of Glioblastoma Heterogeneity
- (2020) Itay Tirosh et al. Cell Stem Cell
- Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
- (2020) Michaël H. Meel et al. CLINICAL CANCER RESEARCH
- CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells
- (2020) Yingxiao Cao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Small molecules, big impact: 20 years of targeted therapy in oncology
- (2020) Philippe L Bedard et al. LANCET
- Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma
- (2020) Wen-Bin Yang et al. NEURO-ONCOLOGY
- Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
- (2020) Catherine Hanna et al. NEURO-ONCOLOGY
- Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
- (2020) Thomas J. Kaley et al. Annals of Clinical and Translational Neurology
- Selective inhibition of CDK4/6: a safe and effective strategy for developing anticancer drugs
- (2020) Kai Yuan et al. Acta Pharmaceutica Sinica B
- Management of glioblastoma: State of the art and future directions
- (2020) Aaron C. Tan et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sequential changes in histone modifications shape transcriptional responses underlying microglia polarization by glioma
- (2020) Marta Maleszewska et al. GLIA
- HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
- (2020) Trang Thi Thu Nguyen et al. JOURNAL OF CLINICAL INVESTIGATION
- PET, image-guided HDAC inhibition of pediatric diffuse midline glioma improves survival in murine models
- (2020) Umberto Tosi et al. Science Advances
- Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
- (2020) Mark Rosenthal et al. ESMO Open
- Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma
- (2020) Zachary Miklja et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
- (2020) Mariko DeWire et al. JOURNAL OF NEURO-ONCOLOGY
- A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
- (2020) Mark R Gilbert et al. NEURO-ONCOLOGY
- Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large‐Scale Data to Inform Therapeutic Directions
- (2020) Denis L. Jardim et al. ONCOLOGIST
- Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
- (2020) Shaozhen Xie et al. Cell Reports
- The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance
- (2020) Filippo Torrisi et al. Cancers
- Upfront treatment with mTOR inhibitor everolimus in pediatric low‐grade gliomas: A single‐center experience
- (2020) Antonella Cacchione et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors
- (2020) Jingyu Zhu et al. MEDICINAL RESEARCH REVIEWS
- How selective are clinical CDK4/6 inhibitors?
- (2020) Denisa Hendrychová et al. MEDICINAL RESEARCH REVIEWS
- Molecular targets of tyrosine kinase inhibitors in thyroid cancer
- (2020) Poupak Fallahi et al. SEMINARS IN CANCER BIOLOGY
- Inhibition of TFEB oligomerization by co-treatment of melatonin with vorinostat promotes the therapeutic sensitivity in glioblastoma and glioma stem cells
- (2019) Gi-Jun Sung et al. JOURNAL OF PINEAL RESEARCH
- MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling
- (2019) Wei Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults
- (2019) Marte Karen Brattås et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma
- (2019) Jingwen Jiang et al. Autophagy
- Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas
- (2019) Rosângela Mayer Gonçalves et al. BIOCHEMICAL PHARMACOLOGY
- Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells
- (2019) Olivia Morris-Hanon et al. MOLECULAR NEUROBIOLOGY
- A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma
- (2019) Ekaterina Pak et al. NEURO-ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872
- (2019) Evanthia Galanis et al. CANCER
- Src and Fyn define a new signaling cascade activated by canonical and non-canonical Wnt ligands and required for gene transcription and cell invasion
- (2019) Aida Villarroel et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort
- (2019) An-Chi Tien et al. CLINICAL CANCER RESEARCH
- IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
- (2019) Geon-Hee Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line
- (2019) Francesco P Cammarata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells
- (2019) Ana Jimenez-Pascual et al. Cancer Discovery
- Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
- (2019) Eudocia Q. Lee et al. Cancer Medicine
- Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
- (2019) Jamie N. Anastas et al. CANCER CELL
- Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
- (2019) John D. Hainsworth et al. JOURNAL OF NEURO-ONCOLOGY
- A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
- (2019) Martin van den Bent et al. JOURNAL OF NEURO-ONCOLOGY
- Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
- (2019) Caroline Von Achenbach et al. JOURNAL OF NEUROCHEMISTRY
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- (2018) David Schiff et al. CANCER
- Combined c-Met/Trk inhibition overcomes resistance to CDK4/6 inhibitors in Glioblastoma
- (2018) Inan Olmez et al. CANCER RESEARCH
- Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas
- (2018) Sharmistha Pal et al. CANCER RESEARCH
- Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression
- (2018) Yu-Ting Wang et al. CANCER SCIENCE
- Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma
- (2018) Yiru Zhang et al. CLINICAL CANCER RESEARCH
- Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells
- (2018) Songlin Liu et al. INVESTIGATIONAL NEW DRUGS
- The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma
- (2018) Claudio Festuccia et al. Journal of Hematology & Oncology
- Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF -Mutated High-Grade Glioma
- (2018) Tanner M. Johanns et al. Journal of the National Comprehensive Cancer Network
- Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products
- (2018) Kodappully S. Siveen et al. Molecular Cancer
- Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
- (2018) Steven T. Sizemore et al. MOLECULAR CANCER RESEARCH
- mTOR inhibition in glioblastoma: requiem for a dream?
- (2018) Sam Babak et al. NEURO-ONCOLOGY
- Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2018) Gerald Edelman et al. ONCOLOGIST
- Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3
- (2018) Zhibo Dai et al. ONCOLOGY REPORTS
- Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma
- (2018) Alberto Broniscer et al. PEDIATRIC BLOOD & CANCER
- MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance
- (2018) Hyojin Eom et al. Artificial Cells Nanomedicine and Biotechnology
- SIRT2‐mediated inactivation of p73 is required for glioblastoma tumorigenicity
- (2018) Kosuke Funato et al. EMBO REPORTS
- Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer.
- (2018) Neil Portman et al. ENDOCRINE-RELATED CANCER
- mTORC1 inhibition in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin
- (2018) Brad Poore et al. NEURO-ONCOLOGY
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015
- (2018) Quinn T Ostrom et al. NEURO-ONCOLOGY
- MiRNA-451 Inhibits Glioma Cell Proliferation and Invasion Through the mTOR/HIF-1α/VEGF Signaling Pathway by Targeting CAB39
- (2018) Yang Nan et al. Human Gene Therapy Clinical Development
- Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells
- (2018) Jia Wei et al. CURRENT CANCER DRUG TARGETS
- Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
- (2018) Francesco Marampon et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Long noncoding RNA MEG3 inhibits proliferation and migration but induces autophagy by regulation of Sirt7 and PI3K/AKT/mTOR pathway in glioma cells
- (2018) Dong-Hui Xu et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Drug development for glioma: are we repeating the same mistakes?
- (2018) Roger Stupp LANCET ONCOLOGY
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2018) Giuseppe Lombardi et al. LANCET ONCOLOGY
- Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca2+-dependent pathway
- (2018) Yihao Zhu et al. Drug Design Development and Therapy
- Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
- (2017) Tian Lan et al. EXPERIMENTAL CELL RESEARCH
- Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme
- (2017) Khaled Greish et al. JOURNAL OF DRUG TARGETING
- Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas
- (2017) Katherine B. Peters et al. JOURNAL OF NEURO-ONCOLOGY
- Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas
- (2017) Mei Liu et al. LABORATORY INVESTIGATION
- Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
- (2017) Hua-fu Zhao et al. Molecular Cancer
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
- (2017) Patrick Y Wen et al. NEURO-ONCOLOGY
- A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
- (2017) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
- (2017) Patrick Flannery et al. ONCOLOGY REPORTS
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- IDH -Mutant Tumors Vulnerable to PARP Inhibition
- (2017) Cancer Discovery
- Improving the Armamentarium of PI3K Inhibitors with Isoform-Selective Agents: A New Light in the Darkness
- (2017) Jordi Rodon et al. Cancer Discovery
- High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response
- (2017) Olatz Arrizabalaga et al. Oncogenesis
- Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting
- (2017) Gretchen L. Gierach et al. JAMA Oncology
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways
- (2016) YiHan Wu et al. BIOMEDICINE & PHARMACOTHERAPY
- HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
- (2016) Yanxin Pei et al. CANCER CELL
- Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity
- (2016) Zhiqiang Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma
- (2016) Roman Reinartz et al. CLINICAL CANCER RESEARCH
- Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
- (2016) Andrew C. Wood et al. CLINICAL CANCER RESEARCH
- Epigenetics in Brain Tumors: HDACs Take Center Stage
- (2016) Ilker Y. Eyüpoglu et al. Current Neuropharmacology
- Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma
- (2016) Shinichi Watanabe et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Role of mTOR in glioblastoma
- (2016) Zekeriya Duzgun et al. GENE
- Targeted inhibition of dominant PI3-kinase catalytic isoforms increase expression of stem cell genes in glioblastoma cancer stem cell models
- (2016) NICOLE M. JONES et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor – belinostat – in glioblastoma cell lines: a preliminary report
- (2016) Magdalena Kusaczuk et al. INVESTIGATIONAL NEW DRUGS
- Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells
- (2016) Ming Luo et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma
- (2016) Caroline Happold et al. JOURNAL OF CLINICAL ONCOLOGY
- Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide
- (2016) Navid Redjal et al. JOURNAL OF NEURO-ONCOLOGY
- Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
- (2016) I. A. Netland et al. JOURNAL OF NEURO-ONCOLOGY
- Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
- (2016) Sebastian I. Arriola Apelo et al. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
- Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling
- (2016) Kristin B. Runkle et al. MOLECULAR CELL
- Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
- (2016) Rikke D. Rasmussen et al. Molecular Oncology
- Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth
- (2016) Rintaro Hashizume et al. NEURO-ONCOLOGY
- EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation
- (2016) Eskil Eskilsson et al. NEURO-ONCOLOGY
- Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines
- (2016) Zong-yang Li et al. NEUROCHEMICAL RESEARCH
- A comprehensive profile of recurrent glioblastoma
- (2016) B Campos et al. ONCOGENE
- Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway
- (2016) Chien-Ju Lin et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
- (2016) Mélissa Carbonneau et al. Nature Communications
- BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma
- (2016) Maria-Carmela Speranza et al. Scientific Reports
- Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system
- (2015) Sebastian I. Arriola Apelo et al. AGING CELL
- A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors
- (2015) H. Henary et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells
- (2015) Lotte M.E. Berghauser Pont et al. CANCER LETTERS
- NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
- (2015) Zhiyun Yu et al. CANCER LETTERS
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients
- (2015) E. Q. Lee et al. CLINICAL CANCER RESEARCH
- NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5
- (2015) KIMBERLY A. FOSTER et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study
- (2015) H. Ian Robins et al. JOURNAL OF NEURO-ONCOLOGY
- Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition
- (2015) M. Mehta et al. MOLECULAR CANCER THERAPEUTICS
- Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
- (2015) Catherine S Grasso et al. NATURE MEDICINE
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma
- (2015) E. Q. Lee et al. NEURO-ONCOLOGY
- Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
- (2015) Melissa M. Singh et al. NEURO-ONCOLOGY
- Dasatinib in recurrent glioblastoma: failure as a teacher
- (2015) David Schiff et al. NEURO-ONCOLOGY
- Prognostic relevance of epilepsy at presentation in glioblastoma patients
- (2015) Sharon Berendsen et al. NEURO-ONCOLOGY
- PKCδ maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback
- (2015) R-K Kim et al. ONCOGENE
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
- (2015) Katrin Liffers et al. Targeted Oncology
- FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells
- (2015) Li Zhang et al. TOXICOLOGY LETTERS
- Role of ErbB Receptors in Cancer Cell Migration and Invasion
- (2015) Aline Appert-Collin et al. Frontiers in Pharmacology
- Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma
- (2015) Jonas Ecker et al. Acta Neuropathologica Communications
- Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors
- (2014) Megumi Inada-Inoue et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PARP inhibitors and IR join forces to strike glioblastoma-initiating cells
- (2014) N Lugli et al. CELL DEATH AND DIFFERENTIATION
- Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase i inhibitor or radiation
- (2014) Francesco Sabbatino et al. CYTOMETRY PART A
- The role of Src family kinases in growth and migration of glioma stem cells
- (2014) XIAOSI HAN et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
- (2014) Phyllis R. Wachsberger et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Sorafenib/Regorafenib and Lapatinib Interact to kill CNS Tumor Cells
- (2014) Hossein A. Hamed et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma
- (2014) Jennie W. Taylor et al. JOURNAL OF NEURO-ONCOLOGY
- Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma
- (2014) Nathalène Truffaux et al. NEURO-ONCOLOGY
- Silencing of protein kinase D2 induces glioma cell senescence via p53-dependent and -independent pathways
- (2014) Eva Bernhart et al. NEURO-ONCOLOGY
- A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma
- (2014) J. L. Clarke et al. NEURO-ONCOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines
- (2014) Joshua C. Anderson et al. RADIOTHERAPY AND ONCOLOGY
- Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF in glioblastoma
- (2014) Y. Kusne et al. Science Signaling
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells
- (2013) M Venere et al. CELL DEATH AND DIFFERENTIATION
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma
- (2013) D. A. Reardon et al. CLINICAL CANCER RESEARCH
- Pazopanib, a new therapy for metastatic soft tissue sarcoma
- (2013) Jaap Verweij et al. EXPERT OPINION ON PHARMACOTHERAPY
- Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival
- (2013) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity
- (2013) Chudi O. Ndubaku et al. JOURNAL OF MEDICINAL CHEMISTRY
- A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
- (2013) Vasilios Karavasilis et al. JOURNAL OF NEUROLOGY
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme
- (2013) David M. Peereboom et al. NEURO-ONCOLOGY
- Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme
- (2013) M. Kerkhof et al. NEURO-ONCOLOGY
- Valproic acid pathway
- (2013) Yogita Ghodke-Puranik et al. Pharmacogenetics and Genomics
- Comparison of HDAC inhibitors in clinical development
- (2013) Thomas Aagaard Rasmussen et al. Human Vaccines & Immunotherapeutics
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
- (2012) Jian Chen et al. CELL
- Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts
- (2012) G. J. Kitange et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
- (2012) C. Leonetti et al. CURRENT CANCER DRUG TARGETS
- PARP-1 protein expression in glioblastoma multiforme
- (2012) A. Galia et al. EUROPEAN JOURNAL OF HISTOCHEMISTRY
- Safety and tolerability of pazopanib in the treatment of renal cell carcinoma
- (2012) Andrea Zivi et al. Expert Opinion On Drug Safety
- Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
- (2012) Katharina Seystahl et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
- (2012) Maja J. A. de Jonge et al. INVESTIGATIONAL NEW DRUGS
- Continuous daily sunitinib for recurrent glioblastoma
- (2012) Teri Nguyen Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
- (2012) E. Q. Lee et al. NEURO-ONCOLOGY
- EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
- (2012) E. Franceschi et al. NEURO-ONCOLOGY
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- PARP-1 Inhibitors DPQ and PJ-34 Negatively Modulate Proinflammatory Commitment of Human Glioblastoma Cells
- (2012) Marina Scalia et al. NEUROCHEMICAL RESEARCH
- Early prediction of response to Vorinostat in an orthotopic rat glioma model
- (2012) Li Wei et al. NMR IN BIOMEDICINE
- Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
- (2011) Genevieve Schindler et al. ACTA NEUROPATHOLOGICA
- eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206
- (2011) Y. Cheng et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
- (2011) D. Koul et al. CLINICAL CANCER RESEARCH
- Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic
- (2011) Jacob E. Shabason et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
- (2011) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas
- (2011) J. J. Raizer et al. NEURO-ONCOLOGY
- Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies
- (2011) P. C. De Witt Hamer NEURO-ONCOLOGY
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
- (2011) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target
- (2011) S. J. Smith et al. NEURO-ONCOLOGY
- Pathway inhibition: emerging molecular targets for treating glioblastoma
- (2011) W. Wick et al. NEURO-ONCOLOGY
- A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
- (2011) Fabio M. Iwamoto et al. NEURO-ONCOLOGY
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
- (2011) M. Weller et al. NEUROLOGY
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
- (2011) Matthew T. Burger et al. ACS Medicinal Chemistry Letters
- Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
- (2010) R A Daniel et al. BRITISH JOURNAL OF CANCER
- Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme
- (2010) John D. Hainsworth et al. CANCER
- Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
- (2010) Manmeet S. Ahluwalia et al. CANCER LETTERS
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) B. McEllin et al. CANCER RESEARCH
- Phase I Study of Vandetanib With Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma
- (2010) Jan Drappatz et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
- (2010) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
- (2010) Margaret J. Dougherty et al. NEURO-ONCOLOGY
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry
- (2010) Maxim Isabelle et al. Proteome Science
- Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
- (2009) D A Reardon et al. BRITISH JOURNAL OF CANCER
- Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
- (2009) David A. Reardon et al. CANCER
- A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
- (2009) Brian Thiessen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
- (2009) Gregor Dresemann et al. JOURNAL OF NEURO-ONCOLOGY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration
- (2008) N. Dey et al. CANCER RESEARCH
- Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas
- (2008) C.-H. Kwon et al. CANCER RESEARCH
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
- (2008) O. Johnston et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma
- (2008) David A. Reardon et al. NEURO-ONCOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- A Phase I Dose-Escalation Study of Fractionated Stereotactic Radiosurgery in Combination With Gefitinib in Patients With Recurrent Malignant Gliomas
- (2007) Amanda L. Schwer et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now